Small molecule inhibitors for both TGFBR1/2 and ACVR1B are available and conceivably could be used as adjuvant therapies in advanced colon cancer, but biomarkers to determine treatment suitability and specifically to avoid augmentation of oncogenic signaling are lacking. This evidence concerns the gene ACVR1B and colonic neoplasm.